What it sells
Agentic operating system that lets pharma staff build teams of AI agents for engineering, scientific and manufacturing tasks.
Business model breakdown
Buyer: who owns the budget?
Pharma leaders in MSAT, quality, manufacturing, CMC, CDMO, and Digital/IT / enterprise AI.
Trigger: what makes them buy now?
Slow, manual evidence assembly for deviation investigations, yield issues and tech transfer; need for governed AI at scale in R&D.
Workflow: what inputs become what output?
Pharma manufacturing and engineering operations
Economics: what it saves and how it charges
Priced per workspace (one molecule, site or trial) with size tiers 1-3 including dedicated or customer-cloud deployment; 5 of the pharma top 20 run Katalyze.
Distribution: how it reaches customers
Demo-led ('Book a Demo'); pricing configurator ends in a call.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-07-06 | Seed | $10.5 million USD ($14.9 million CAD) | Bonfire Ventures (lead), Inovia Capital, Ripple Ventures | betakit.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.